MYH9
MYH9 (myosin heavy chain 9), also known as NMMHCA, NMHC-II-A and MHA, encodes the heavy chain of non-muscle myosin IIA, a conventional class II myosin. It contributes to cytokinesis, cell motility and the maintenance of cell shape. Browse Assay Genie's current range of MYH9 research reagents below, or read on for the biology behind the target.
MYH9 encodes a conventional non-muscle myosin, the myosin IIA heavy chain. The protein contains an IQ domain and a myosin head-like domain, and this region is involved in several important cellular functions, including cytokinesis, cell motility and the maintenance of cell shape. It belongs to the myosin family within the TRAFAC class myosin-kinesin ATPase superfamily. In the literature the protein is also called myosin-9, NMMHCA or NMHC-II-A.
UniProt records the protein in the cytoplasm, where it is found in the cytoskeleton and the cell cortex. It is also annotated in cortical granules, a type of secretory vesicle, and at the cell membrane. In a microbial infection context, myosin-9 acts as a receptor for the envelope glycoprotein B of herpes simplex virus 1 (HHV-1). The MYH9 gene should not be confused with the unconventional myosins MYO9A and MYO9B, which are separate genes.
The gene is a member of the HGNC group of myosin heavy chains, class II, and also of the group of microRNA protein coding host genes. Its previous name was myosin, heavy polypeptide 9, non-muscle. Defects in MYH9 are associated with several human conditions: non-syndromic sensorineural deafness autosomal dominant type 17 (DFNA17), Epstein syndrome (EPSTS), Fechtner syndrome (FTNS), Sebastian syndrome, Alport syndrome with macrothrombocytopenia, and macrothrombocytopenia with progressive sensorineural deafness. Mouse and rat both carry an orthologous Myh9 gene.
Myosin IIA helps maintain cell shape, so MYH9 is a natural focus for studies of cortical and cytoskeletal organisation.
The myosin head-like domain of MYH9 is involved in cytokinesis and cell motility, making it relevant to division and migration research.
Defects in MYH9 are linked to Epstein, Fechtner and Sebastian syndromes and to Alport syndrome with macrothrombocytopenia.
MYH9 variants are associated with autosomal dominant deafness type 17 and with macrothrombocytopenia with progressive sensorineural deafness.
MYH9 encodes the heavy chain of non-muscle myosin IIA. Its IQ domain and myosin head-like domain are involved in cytokinesis, cell motility and the maintenance of cell shape. UniProt also notes that it acts as a receptor for herpes simplex virus 1 envelope glycoprotein B.
Aliases include NMMHCA, NMHC-II-A, MHA, FTNS, EPSTS and DFNA17. The UniProt name is myosin-9, and the previous HGNC name was myosin, heavy polypeptide 9, non-muscle. It is distinct from the unconventional myosins MYO9A and MYO9B.
Defects in MYH9 are associated with Epstein syndrome, Fechtner syndrome, Sebastian syndrome, DFNA17 deafness and Alport syndrome with macrothrombocytopenia. Mouse and rat both have an orthologous Myh9 gene; check the datasheet of any product for its validated reactivity.
Other class II myosin heavy chain genes that sit alongside MYH9 in cytoskeleton and motor protein research.
Gene and protein annotations from HGNC, NCBI Gene and UniProt P35579; product specifications from Assay Genie datasheets.